Mesa Labs Q4 Loss of $4.1M on $63.7M Revenue; FY Revenue Up 3.4%
MLAB•Mesa Laboratories recorded a $4.1 million net loss in fiscal Q4, or $0.75 per share, on $63.7 million revenue, while non-GAAP earnings reached $2.76 per share. Annual revenue rose 3.4% to $249.1 million with operating income up 13.3% to $18.5 million and non-GAAP margin at 25.5%, while $14.7 million debt reduction cut leverage to 2.11×.
1. Fiscal Results
Mesa Laboratories reported a fiscal Q4 net loss of $4.1 million, or $0.75 per share, on $63.7 million revenue, while non-GAAP earnings were $2.76 per share. For fiscal 2026, revenue grew 3.4% to $249.1 million, net income reached $6.7 million, or $1.21 per share.
2. Margin and Income
Operating income in Q4 rose 87% year-over-year to $2.7 million, with non-GAAP adjusted operating income at 28.7% of revenue. Full-year operating income increased 13.3% to $18.5 million, and non-GAAP margin expanded to 25.5%, reflecting cost realignment benefits and favorable product mix.
3. Division Performance
Sterilization and Disinfection Control division saw 17.7% organic revenue growth to $29.1 million in Q4, driven by backlog reduction and volume gains. Biopharmaceutical Development revenues declined amid export control delays on peptide systems, while Clinical Genomics remained stable, with core organic growth expected to return in Q1.
4. Financial Position and Outlook
The company generated $39.6 million of free cash flow and repaid $14.7 million of debt, lowering its net leverage ratio to 2.11×. Leadership highlighted a 100-day business review by the CEO and anticipates providing full-year guidance following the release of first-half results.
